ROBERT CHAMBLISS: Open Payments
NPI 1780611202 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,293 in 46 payments from 15 companies in 2025. Trend: 2023 $186 · 2024 $729 · 2025 $1,293
Food & beverage: $1,112Education: $181
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $289 |
| Teva Pharmaceuticals USA, Inc. | 5 | $230 |
| Otsuka America Pharmaceutical, Inc. | 5 | $209 |
| E.R. Squibb & Sons, L.L.C. | 3 | $80 |
| Alkermes, Inc. | 4 | $79 |
| ABBVIE INC. | 5 | $77 |
| Collegium Pharmaceutical, Inc. | 4 | $69 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
| Lundbeck LLC | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
Products named: SPRAVATO, ABILIFY ASIMTUFII, COBENFY, ARISTADA, VRAYLAR, Jornay PM, REXULTI, INGREZZA.
Industry payments across PA — which companies pay providers there.
